8-KEarnings & ResultsExhibits & Filings

Merck & Co., Inc. 8-K Report, Financial Results (Feb 4, 2015)

Filed February 4, 2015For Securities:MRK

Summary

Merck & Co., Inc. (MRK) filed an 8-K on February 4, 2015, to report its financial results for the fourth quarter and full year ended December 31, 2014. The filing primarily incorporates by reference a press release (Exhibit 99.1) and supplemental financial information (Exhibit 99.2) that detail the company's performance. Investors should review these attached documents for specific financial figures, including revenue, earnings per share, and any forward-looking guidance provided by the company. This 8-K serves as the official disclosure mechanism for this key financial information.

Key Highlights

  • 18-K filing on February 4, 2015, reporting Q4 and Full Year 2014 financial results.
  • 2Key financial details are provided through incorporated press release (Exhibit 99.1).
  • 3Supplemental financial information not in the press release is also incorporated (Exhibit 99.2).
  • 4Filing falls under Item 2.02 (Results of Operations and Financial Condition).
  • 5Information furnished is not deemed 'filed' under Section 18 of the Exchange Act, but is incorporated by reference in certain filings.
  • 6The 8-K provides official notification of Merck's financial performance for the specified periods.

Frequently Asked Questions

The primary purpose of this 8-K filing by Merck & Co., Inc. is to officially report its financial results for the fourth quarter and the full year ended December 31, 2014. It incorporates by reference a press release and supplemental financial information containing these results.

The detailed financial results are not directly included in the body of the 8-K itself. Instead, they are provided in Exhibit 99.1 (the press release) and Exhibit 99.2 (supplemental information), which are incorporated by reference into this filing.

While the 8-K filing itself does not directly present forward-looking statements, the incorporated press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) are likely to contain such details regarding Merck's performance outlook. Investors should carefully review these exhibits for any guidance provided.

This disclaimer means that the information furnished under Item 2.02 is not subject to the strict liability provisions of Section 18 of the Securities Exchange Act of 1934. However, it can still be incorporated by reference into other filings, such as registration statements under the Securities Act of 1933, where it would be subject to liability.